Souhaitez-vous accéder aux communiqués récents ?

Unity® Consortium urges families to keep young people up to date on well-visits and vaccinations during Adolescent Immunization Action Week (AIAW26).

Enrollment completed in CHAPTER-3, a pivotal study of deucrictibant XR for prophylactic treatment of HAE attacks; topline data anticipated in 3Q2026Timeline for submission of NDA dossier of...

New York, NY , April 01, 2026 (GLOBE NEWSWIRE) -- Akchuli Medical, a healthcare price-transparency marketplace, today announced the launch of its platform designed to connect patients directly...

PHILADELPHIA, March 30, 2026 (GLOBE NEWSWIRE) -- Medicus Pharma Ltd. (NASDAQ: MDCX) ("Medicus" or the "Company"), a biotech/life sciences company focused on advancing the clinical development...

In the Phase 2 part of the AMETHYST study, litifilimab met the primary endpoint of reduction of disease activity in people living with CLE at Week 16, with more litifilimab participants achieving...

Featured presentation highlights positive BroADen Phase 1b atopic dermatitis trial results supporting KT-621’s compelling oral profile Parallel Phase 2b trials, BROADEN2 in atopic dermatitis and...

WILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (“Monopar,” the “Company,” “we”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company developing innovative...

First Patient Dosed (FPD) in Phase 2a MAINSAIL Trial of NAV-240 in Hidradenitis Suppurativa (HS)Phase 1b Multiple Ascending Dose Study Demonstrates Favorable Profile for NAV-240 First Participant...

Austin, TX, USA, March 26, 2026 (GLOBE NEWSWIRE) -- Healthcare Foresights has published a new research report titled “ Size, Trends and Insights By Product (Wearables, Sleep Trackers, Smart Beds and...

MELBOURNE, Australia and NEW YORK, March 25, 2026 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL), a clinical-stage biopharmaceutical company developing combination therapies for...